Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution

Peritoneal Dialysis International

Volumn 29, Issue 6, 2009, Pages 647-655

  Weiss, Lars ^a   Stegmayr, Bernd ^b   Malmsten, Gudrun ^c   Tejde, Mattias ^d   Hadimeri, Henrik ^e   Siegert, Carl E ^f   Ahlmén, Jarl ^g   Larsson, Rutger ^h   Ingman, Bo ⁱ   Simonsen, Ole ^j   van Hamersvelt, Henk W ^k   Johansson, Ann C ^j   Hylander, Britta ^l   Mayr, Michael ^m   Nilsson, Per Henrik ⁿ   Andersson, Per O ^o   De los Ríos, Tatiana ^p  

^a Department/Division of Nephrology   (Sweden)

^b Universitetssjukhuset   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d FALUN HOSPITAL   (Sweden)

^e Höglandsjukhuset Eksjöklinikerna   (Sweden)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g Karnsjukhuset   (Sweden)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

ⁱ SUNDERBY HOSPITAL   (Sweden)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ Centrallasarettet   (Sweden)

^o VRINNEVI HOSPITAL   (Sweden)

^p FRESENIUS MEDICAL CARE   (Germany)

more..

Author keywords

Biocompatibility; Cancer antigen 125; Peritoneal dialysis fluids; Purely bicarbonate buffered; Residual renal function

Indexed keywords

BICARBONATE; BICARBONATE BUFFERED PERITONEAL DIALYSIS SOLUTION; BUFFER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CREATININE; DIALYSIS FLUID; GAMMA INTERFERON; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; HYALURONIC ACID; INTERLEUKIN 6; LACTIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; VASCULOTROPIN;

ACID BASE BALANCE; ADULT; ANALYTICAL PARAMETERS; ANTIGEN DETECTION; ARTICLE; BIOCOMPATIBILITY; BLOOD CARBON DIOXIDE TENSION; BLOOD OXYGEN TENSION; BLOOD PH; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSATE; DIALYSATE LEVEL; DIALYSATE TO PLASMA CREATININE RATIO; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; OPEN STUDY; PAIN ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL RENAL FUNCTION; TREATMENT DURATION; ULTRAFILTRATION; URINE VOLUME; VENOUS BLOOD; VISUAL ANALOG SCALE;

EID: 77954337529     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.1177/089686080902900610     Document Type: Article

References (38)

1. Feriani M, Biasioli S, Chiaramonte S, Bragantini L, Brendolan A, Dell'Aquila R, et al. Will bicarbonate-CAPD strengthen the natural defence by having a physiological pH and a natural buffer? Contrib Nephrol 1987; 57:101-9.
2. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick- Deetjen J, et al. In vitro formation of N(epsilon)-(carboxymethyl) lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280:1408-14.
3. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/ lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67:1559-65.
4. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
5. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
6. Topley N, Kaur D, Petersen MM, Jorres A, Passlick-Deetjen J, Coles GA, et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 1996; 49:1447-56.
7. Jorres A, Bender TO, Finn A, Witowski J, Frohlich S, Gahl GM, et al. Biocompatibility and buffers: effect of bicarbonate- buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54:2184-93.
8. Plum J, Razeghi P, Lordnejad RM, Perniok A, Fleisch M, Fussholler A, et al. Peritoneal dialysis fluids with a physiologic pH based on either lactate or bicarbonate buffer- effects on human mesothelial cells. Am J Kidney Dis 2001; 38:867-75.
9. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14:1296-306.
10. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003; 14:2632-8.
11. Cancarini GC, Faict D, De Vos C, Guiberteau R, Tranaeus A, Minetti L, et al. Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate. Perit Dial Int 1998; 18:576-82.
12. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061-7.
13. Henderson IS, Couper IA, Lumsden AB. Potentially irritant glucose metabolites in unused CAPD fluid. In: Maher JF, Winchester JF, eds. Frontiers in Peritoneal Dialysis. New York: Field, Rich and Associates; 1986.
14. Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54:1731-8.
15. Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10:64-9.
16. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
17. Burckhardt CS, Bjelle A. A Swedish version of the shortform McGill Pain Questionnaire. Scand J Rheumatol 1994; 23:77-81.
18. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
19. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529-38.
20. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
21. Bouts AH, Groothoff JW, van Amstel SP, Zweers MM, Davin JC, Krediet RT. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis. Adv Perit Dial 2000; 16:328-31.
22. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21:560-7.
23. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19:2101-6.
24. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51:888-93.
25. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products- a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552-9.
26. Theodoridis M, Passadakis P, Kriki P, Gioka T, Panagoutsos S, Mourvati E, et al. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability. Ren Fail 2008; 30:161-7.
27. Hömme M, Hackert T, Schäfer J, Schaefer F, Schmitt CP. Peritoneal dialysis solutions acutely regulate CA125 expression in human primary mesothelial cells [Abstract]. J Am Soc Nephrol 2007; 18:74A.
28. Yung S, Chan TM. Hyaluronan-regulator and initiator of peritoneal inflammation and remodeling. Int J Artif Organs 2007; 30:477-83.
29. Yung S, Coles GA, Williams JD, Davies M. The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 1994; 46:527-33.
30. Mackenzie RK, Holmes CJ, Moseley A, Jenkins JP, Williams JD, Coles GA, et al. Bicarbonate/lactate- and bicarbonate- buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. J Am Soc Nephrol 1998; 9:1499-506.
31. Martikainen TA, Teppo AM, Gronhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25:453-60.
32. Liberek T, Lichodziejewska-Niemierko M, Knopinska- Posluszny W, Schaub TP, Kirchgessner J, Passlick-Deetjen J, et al. Generation of TNFalpha and interleukin-6 by peritoneal macrophages after overnight dwells with bicarbonate- or lactate-buffered dialysis fluid. Perit Dial Int 2002; 22:663-9.
33. Fieren MW, van den Bemd GJ, Bonta IL, Ben Efraim S. Peritoneal macrophages from patients on continuous ambulatory peritoneal dialysis have an increased capability to release tumour necrosis factor during peritonitis. J Clin Lab Immunol 1991; 34:1-9.
34. Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007; 22:2038-44.
35. Montenegro J, Saracho RM, Martinez IM, Munoz RI, Ocharan JJ, Valladares E. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26:89-94.
36. Fang W, Mullan R, Shah H, Mujais S, Bargman JM, Oreopoulos DG. Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover singledwell study. Perit Dial Int 2008; 28:35-43.
37. Konings CJ, Kooman JP, van der Sande FM, Leunissen KM. Fluid status in peritoneal dialysis: what's new? Perit Dial Int 2003; 23:284-90.
38. Feriani M, Passlick-Deetjen J, Jaeckle-Meyer I, La Greca G. Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients. Nephrol Dial Transplant 2004; 19:195-202.